GlaxoSmithKline increases share in Theravance

Drugs giant GlaxoSmithKline has agreed to up its stake in US biotech firm Theravance, its partner in lung medicine Relovair.

GlaxoSmithKline increases share in Theravance

Drugs giant GlaxoSmithKline has agreed to up its stake in US biotech firm Theravance, its partner in lung medicine Relovair.

It is to pay $212.9m (€159.5m) to increase its holding from 18.3% to 26.8%.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited